Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 7/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.67 |
| ▸ | NOS1 | P29475 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78658 | 1.00 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL8157616 | 0.98 | SIGMAR1 (0.96) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Bromide SCHEMBL30258978 | 0.98 | SIGMAR1 (0.96) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003076 | 0.87 | SIGMAR1 (0.76) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003079 | 0.87 | SIGMAR1 (0.83) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003083 | 0.87 | SIGMAR1 (0.76) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Sulfuric Acid SCHEMBL8168521 | 0.86 | SIGMAR1 (0.74) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4104665 | 0.84 | SIGMAR1 (0.71) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29970300 | 0.82 | SIGMAR1 (0.69) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003080 | 0.82 | SIGMAR1 (0.69) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768807-A1 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | Chevron Oronite Company LLC (US) | 2021-01-27 | — | — | EP | claimed |
| CN-112055742-A | Composition and method for preventing or reducing low speed pre-ignition in spark-ignition internal combustion engines | 雪佛龙奥伦耐有限责任公司 | 2020-12-08 | — | — | CN | claimed |
| WO-2020194041-A2 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | CHEVRON ORONITE COMPANY LLC (US) | 2020-10-01 | — | — | WO | claimed |
| WO-2019180685-A1 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | CHEVRON ORONITE COMPANY LLC (US) | 2019-09-26 | — | — | WO | claimed |
| US-20190292473-A1 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | CHEVRON ORONITE COMPANY LLC | 2019-09-26 | — | — | US | claimed |
| US-9944593-B2 | Process for the synthesis of fluoralkyl sulfonate salts | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2018-04-17 | — | — | US | claimed |
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4603565-A2 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | Chevron Oronite Company LLC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4105262-B1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORP (JP) | 2025-04-02 | — | — | EP | disclosed |
| EP-3880771-B1 | COMPOSITION AND METHOD FOR PREVENTING OR REDUCING LOW SPEED PRE-IGNITION IN SPARK-IGNITED INTERNAL COMBUSTION ENGINES | CHEVRON ORONITE CO (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240417559-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2024-12-19 | — | — | US | disclosed |
| US-20100004367-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2123720-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2100923-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-1992665-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1990370-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1808456-A1 | Rubber composition and tire | Continental Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-0330151-A2 | Bag for the storage of blood platelets | NISSHO CORPORATION (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | SIGMAR1 837/4885GRIN2D 1604/4885GRIN3B 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.